For research use only. Not for human consumption. Not medical advice — consult a licensed clinician.

Nootropic / Cognitive

Dermorphin

Also known as: DRM

Banned

Naturally occurring heptapeptide first isolated from the skin of South American Phyllomedusa frogs. It is a highly selective, potent agonist of the mu-opioid receptor (MOR), reported to be roughly 30-40 times more potent than morphine on a molar basis, with low affinity for delta-opioid receptors. Its activity depends on the unusual D-alanine residue at position 2 (one of the few vertebrate peptides containing a D-amino acid) and C-terminal amidation, which confer resistance to peptidases. Dermorphin is not an approved human drug and has no legitimate clinical or nootropic use; it is studied as a pharmacological probe of opioid signaling.

Where to buy · live market data

Who's worth your money for Dermorphin

Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.

Top Merit pick

Highest Merit Score (43) of 1 scored sellers

$7.20/mg

$36.00 · 5mg

no COAs yet

Average price

$7.20/mg

Sellers

1

45-day trend

0%

1 of 1 sellers have a current price

Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.

Watch Dermorphin

Get one email when the market actually moves — no newsletter, no noise.

Compound reference

About Dermorphin

CAS

77614-16-5

Molecular formula

C40H50N8O10

Sequence

Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2

Typical dose range

No established or legitimate human dose; used only at experimental quantities in laboratory animal studies

Half-life

Not well characterized in humans; the D-Ala and C-terminal amide confer greater enzymatic stability than typical endogenous opioid peptides

Common research uses

research probe for mu-opioid receptor pharmacologyanalgesia studies (animal models)no approved or evidence-based human/nootropic use

Safety notes

Not FDA-approved; a potent opioid agonist with the attendant risks of respiratory depression, sedation, dependence, and overdose. Dermorphin gained notoriety as an illicit performance-enhancing 'frog juice' doping agent in horse racing and is a Class 1 prohibited substance in equine competition; in human sport it falls under WADA narcotics. Possession/use outside controlled research is illegal in most jurisdictions.

Independent evidence

COAs for Dermorphin

1 third-party test across 1 vendor. Each card links to the full report.

All 1 COAs for Dermorphin →
Measured purity over time
Research depth

12 citations indexed for Dermorphin

All research on Dermorphin →

animal · 2026

Dermorphin blocks apneic response to intravenous bolus injection of fentanyl

Background Sudden death induced by intravenous bolus (IVb) injection of overdose fentanyl is the major cause of overdose opioid-induced deaths; however, the relevant countermeasure is lacking.

Study · 2026

Nanoassembly-enabled aqueous solid-phase peptide synthesis (ASPPS): a practical DMF-free approach based on the Fmoc strategy

The urgent need for sustainable peptide manufacturing has accelerated efforts to replace conventional N , N -dimethylformamide (DMF)-based solid-phase peptide synthesis (SPPS) with greener alternatives.

Study · 2026

Differential opioid receptor expression and biochemical coupling profiles on glia

The opioid receptor family comprises classical; MOP (mu/µ), KOP (kappa/k), DOP(delta/δ) receptors along with non-classical Nociceptin/Orphanin FQ (N/OFQ) peptide receptor (NOP). Expression on glial cells is controversial where there is a role for glia and opioids in pain processing and immunomodulation.

Study · 2026

Receptor Binding, Functional Activity, and Cell Viability Assessment of Novel Marine-Based Hybrid Peptides from <i>Raja porosa</i>

The hybrid approach remains a compelling strategy for designing molecules that combine enhanced biological activity with a favorable safety profile. Marine peptides, in particular, have attracted significant attention due to their well-documented broad spectrum of biological activities.

animal · 2025

The Neurotropic Activity of Novel Dermorphin Analogs Active at Systemic and Noninvasive Administration

The neuropeptide's multifaceted involvement in various components of neural homeostasis impacts pain and behavioral regulation. One of the highly potent neuropeptides is dermorphin, extracted from the skin of the Amazon frog ( Phyllomedusa sauvagei ).

animal · 2025

Respiratory and Cardiovascular Activity of LENART01, an Analgesic Dermorphin-Ranatensin Hybrid Peptide, in Anesthetized Rats

Opioids are among the most effective drugs for treating moderate to severe pain. Unfortunately, opioid use, even short-term, can lead to addiction, tolerance, overdose, and respiratory depression.